Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer

This publication has 9 references indexed in Scilit:

• Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation
  Journal of Thoracic Oncology, 2012
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
  The Lancet Oncology, 2012
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
  Journal of Clinical Oncology, 2011
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
  New England Journal of Medicine, 2010
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
  Clinical Lung Cancer, 2009
• Epidermal growth factor receptor mutations in lung cancer
  Nature Reviews Cancer, 2007